AB PA01

Drug Profile

AB PA01

Alternative Names: AB-PA01; Ampliphage 001

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation; Westmead Institute for Medical Research
  • Class Antibacterials; Antiglaucomas; Bacteriophages; Quinoxalines; Vasoconstrictors
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Pseudomonal infections

Most Recent Events

  • 19 Mar 2018 AmpliPhi Biosciences Corporation collaborates with the Western Sydney Local Health District and the Westmead Institute for Medical Research on expanded access of AB PA01 for Pseudomonal infections
  • 19 Mar 2018 AmpliPhi Biosciences Corporation intends to submit data from an expanded access programme to the US FDA in mid-2018 to obtain feedback on the path to regulatory approval for AB PA01 in Pseudomonal infections
  • 13 Mar 2018 AmpliPhi Biosciences Corporation establishes CRADA with Department of Veterans Affairs for expanded access of AB PA01 in Pseudomonal infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top